In brief
Researchers are optimistic about a new mango-flavored pill formulated to combat intestinal worms, particularly in developing countries. Early trials indicate it may be more effective than current treatments, signaling a potential breakthrough in a persistent health challenge.
A new mango-flavored pill developed to treat intestinal worms has emerged as a potential game-changer in combating parasitic infections that afflict around 1.5 billion individuals worldwide. Researchers say the promising results from clinical trials suggest that this innovative formulation, which combines two existing anti-parasitic medications, could significantly enhance treatment efficacy.Intestinal worms, often contracted through contaminated food or water, lead to severe gastrointestinal issues, malnutrition, and anemia. Particularly rampant in regions with inadequate sanitation, these parasites—classified as soil-transmitted helminths (STHs)—primarily affect children, making the development of new treatments essential.Findings from the "ALIVE" study, recently published in the Lancet, highlight the pill's potential to advance global health initiatives aimed at meeting World Health Organization targets for disease eradication. The treatment can be taken as a single pill or in a regimen of three tablets over consecutive days, providing ease of administration in mass treatment programs.Prof. Jose Muñoz, the project leader, emphasizes that the simplicity of a single-pill dosage can significantly simplify the treatment process. He also notes that by combining two drugs with distinct mechanisms of action, the risk of drug resistance among the parasites may be mitigated.Current treatments like albendazole have shown declining effectiveness against certain STH species, raising concerns about future management of these infections. During a clinical trial involving 1,001 children aged 5-18 conducted in Ethiopia, Kenya, and Mozambique, the new combination treatment demonstrated greater effectiveness across different types of infections, particularly when used alongside ivermectin. However, the study results did not offer conclusive evidence regarding threadworm treatment specifically.Although experts like Prof. Hany Elsheikha from the University of Nottingham regard the pill as a significant advancement, they acknowledge existing gaps in research, particularly regarding its efficacy across diverse age groups and global regions. The ongoing studies are critical, as the trial's results have been submitted to regulatory bodies in Europe and Africa, with decisions anticipated in early 2025. Further trials are being initiated to recruit 20,000 participants in Kenya and Ghana, reflecting optimism about the pill's potential to transform treatment and improve community health outcomes.Dr. Stella Kepha, a researcher at the Kenya Medical Research Institute, believes the pill could profoundly improve the health of communities impacted by intestinal worms; however, acknowledges there’s still considerable work required before widespread rollout can occur.
